Dr Reddy’s gets USFDA Form 483: 7 notes in 2025

What the USFDA action signals

Dr. Reddy’s Laboratories Ltd. has received a Form 483 with seven observations from the US Food and Drug Administration (USFDA) for its formulations manufacturing facility in Srikakulam, Andhra Pradesh. The company disclosed the development in a regulatory filing, which was reported by PTI. The inspection at the site included both a Good Manufacturing Practices (GMP) inspection and a Pre-Approval Inspection (PAI). According to the disclosure, the inspection was conducted from July 10 to July 18, 2025. Form 483 observations are typically issued when investigators note conditions that may violate the Food, Drug and Cosmetic (FD&C) Act. While a Form 483 is not a final determination, it is closely tracked by investors because it can influence product approvals and compliance timelines.

Inspection details: GMP plus pre-approval review

Dr. Reddy’s said the USFDA completed a GMP and PAI at its formulations manufacturing facility, referred to as FTO 11, in Srikakulam. The company’s filing stated that the USFDA issued a Form 483 with seven observations. The PAI timeline was also specified as July 10 to July 18, 2025. A combined GMP inspection and PAI matters because it can cover both the site’s overall quality systems and readiness for specific product approvals. Any observations raised during a PAI can become particularly important for schedules tied to pending approvals.

What a Form 483 is and what companies must do next

A Form 483 is issued at the conclusion of an inspection when USFDA investigators observe conditions that may be in violation of the FD&C Act. The document is presented and discussed with senior management at the end of the inspection. It serves as a written notice to the company’s management about objectionable conditions found at the facility. Companies are encouraged to respond in writing with corrective actions. The typical window cited for a detailed response is within 15 working days, explaining corrective measures and timelines. The Form 483, by itself, does not represent the agency’s final position on compliance.

Company response: commitment to address observations

In its stock exchange intimation, Dr. Reddy’s said it had been issued a Form 483 with seven observations. The company added that it would address the observations within the stipulated timeline. No further operational or product-specific impact was provided in the disclosed text. The company also did not provide additional commentary on remediation steps in the excerpts shared.

Summary of the reported seven observations at the sterile site

In the information shared, a summary was provided of seven major findings linked to a sterile drug manufacturing facility in Pydibhimavaram, Andhra Pradesh, following the July 10 to July 18, 2025 inspection. The summary points to issues spanning sterility assurance, aseptic validation, inspection practices, equipment qualification, in-process controls, quality review, and CAPA execution.

The listed points include alleged gaps in procedures meant to prevent microbial contamination, such as allowing non-sterile materials during setup and cleaning of Grade A equipment, and the absence of a requirement that sanitization agents be sterile. The summary also cites deficiencies in aseptic process validation, including inadequate smoke visualization and poor unidirectional airflow during airflow studies. It further notes concerns around visual inspection for particulate matter, stating that inspectors did not rotate vials 360 degrees and did not consistently use appropriate contrasting backgrounds.

The summary additionally flags the use of equipment not qualified for capacity in injection product compounding, with a stated risk of carryover due to sub-lot processing in large commercial batches. It also lists in-process control issues, including a lack of verification of critical process parameter measurements after transfers between stages and reliance on vessel sensor data without confirming accuracy. On quality review, the summary cites missing documentation in LIMS for microbial count verifications, missing fill weight scale print slips, and an absence of second-person verification. Finally, it describes ineffective CAPA for recurring issues, including repeated Grade A excursions tied to unclean equipment, recurrent out-of-specification results for a product, training updates not reflected in SOPs or training plans, and a CAPA for visual inspection defect rates not implemented as required in batch manufacturing records.

Key themes raised: sterility, validation, and oversight

Across the items described in the shared summary, the common thread is control of contamination risk in aseptic operations. For sterile manufacturing, areas such as Grade A practices, airflow studies, and inspection discipline are central to product quality assurance. The observations as summarised also extend beyond shop-floor execution into quality systems, including batch documentation, data completeness, and supervisory review. The mention of recurring issues and CAPA effectiveness, if reflected in the final Form 483, would place focus on how sustainably the site resolves deviations and repeats.

Track record: other Dr Reddy’s sites and past Form 483s

The July 2025 Form 483 follows other USFDA observations reported at Dr. Reddy’s facilities in recent years. On November 21, 2024, Dr Reddy’s said a GMP inspection had been completed at its API manufacturing facility (CTO-2) in Bollaram, Hyderabad, conducted between November 13 and November 19, 2024. Following that inspection, the USFDA issued a Form 483 containing seven observations, and the company committed to addressing them within the prescribed timeline.

Separately, Dr. Reddy’s informed exchanges that its biologics manufacturing facility at Bachupally in Hyderabad received a Form 483 with nine observations after a product-specific pre-approval inspection conducted from October 4 to October 12, 2023, and that it would address the concerns within the specified time frame.

Market context: what was disclosed about the stock

In the November 2024 update related to the Bollaram API facility, it was reported that Dr Reddy’s shares closed at ₹1,192.80 on the National Stock Exchange, down 1.70% from the previous close. That report also stated the stock had gained 5.62% over one year and 2.45% since the beginning of the year. No stock move was provided in the July 2025 filing excerpts shared here.

Key facts table

What to watch next

The next formal step is Dr. Reddy’s written response to the Form 483 within the expected timeline, detailing corrective measures and implementation plans. Investors typically watch for any follow-up communication on the classification of the inspection and whether any product approvals are affected, especially when a PAI is involved. Any further details on the nature of the observations, if disclosed later, will help clarify whether issues are procedural, equipment-related, or linked to broader quality system controls. For now, the confirmed facts are the July 2025 inspection window, the combined GMP and PAI scope, and the issuance of seven observations.